The bacteria in our gut affect our lives and our health in ways we are just starting to fully realize, and mapping this biome is expected to advance medical science and pharmacology as mapping the human genome.

However, our gut biota is not a mappable sequence, but a complex ecosystem, and one that may be unique to each individual.

In our conversation, Shinji Fukuda, founder of Metabologenomic (aka Metagen), explains how the science is advancing, what kinds of consumer devices we are likely to see first, the importance of global expansion, and the challenges of being a deep-tech startup in Japan.

It's a great conversation, and I think you'll enjoy it.